Results 231 to 240 of about 6,289,424 (361)

Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study

, 2023
Weiming Wu, Shujie Li, Ke Xu, Zhaowei Meng   +3 more
openalex   +2 more sources

Estimation of the 2-sample hazard ratio function using a semiparametric model.

Biostatistics, 2011
Song Yang, R. Prentice
semanticscholar   +1 more source

Long‐Term Temporal Profile of Motor Recovery After Intracerebral Hemorrhage

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Limited data is available to describe the temporal profile of long‐term recovery over 1 year after the stroke in patients with spontaneous intracerebral hemorrhage (ICH). Methods A registered multicentral cohort was conducted to consecutively include non‐herniated supratentorial ICH patients from November 2013 to January 2023 ...
Yan Zheng, Fu‐Xin Lin, Ling‐Yun Zhuo, Jian‐Cai Chen, Xin Ge, Xiang‐Lin Chen, Xue‐Jiao Wang, Zhi‐Gang Yao, You‐Liang Tong, Bo Xie, Bai‐Hai Guo, Zhao‐Sheng Sun, Zhi‐Hua Tian, Ping Qiu, Xin‐Ru Lin, Qiu He, Shu‐Na Huang, Ke Ma, Fang‐Yu Wang, Huang‐Cheng Shang‐Guan, Wen‐Hua Fang, Deng‐Liang Wang, Ying Fu, Yuan‐Xiang Lin, De‐Zhi Kang   +24 more
wiley   +1 more source

MSR43 Survival Estimates Using Hazard Ratios Derived from Network Meta-Analyses: Recommendations for Reference Curves

, 2023
T. Kloska, Huw Fox, Eva Kaiser, van Hest N   +3 more
openalex   +1 more source

In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell
Benjamin J. Murdock, Jihyun Park, Dae‐Gyu Jang, Bangyao Zhao, Samuel J. Teener, Ian F. Webber‐Davis, Lili Zhao, Eva L. Feldman, Stephen A. Goutman   +8 more
wiley   +1 more source

Propensity score matching for estimating a marginal hazard ratio. [PDF]

Stat Med
Wang T, Zhao H, Yang S, Tang S, Cui Z, Li L, Faries DE.   +6 more
europepmc   +1 more source

Hazard Ratio Bias in Cohort Studies

Epidemiology, 2013
Wen-Chung Lee, Jia-Chun Lin
openaire   +2 more sources

High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia, Jie Lin   +10 more
wiley   +1 more source

Introducing a new estimator and test for the weighted all-cause hazard ratio. [PDF]

BMC Med Res Methodol, 2019
Ozga AK, Rauch G.
europepmc   +1 more source

Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer. [PDF]

Transl Lung Cancer Res, 2020
Chen H, Horita N, Ito K, Hara Y, Kobayashi N, Kaneko T.   +5 more
europepmc   +1 more source